May 30, 2026 - 17:49

Futurum Group has signed a definitive agreement to acquire Aptiviti Inc., the parent company behind Enterprise Technology Research (ETR). The deal aims to merge ETR's institutional-grade data on technology spending with Futurum's existing research, advisory, and intelligence capabilities.
The acquisition is expected to expand Futurum's predictive technology intelligence platform by adding ETR's large-scale survey data and spending intent signals. ETR is known for tracking enterprise IT buying patterns, providing a look at where budgets are flowing and which vendors are gaining or losing ground. By combining that data with Futurum's analyst-led research and strategic advisory services, the company hopes to offer clients a more complete picture of the technology landscape.
Futurum Group has been building out its research and advisory offerings over the past few years, positioning itself as a competitor to larger firms in the space. This deal marks a significant step in that direction, giving it direct access to a proprietary data set that many enterprises and vendors already rely on for planning and benchmarking.
Financial terms of the transaction were not disclosed. The deal is expected to close in the coming weeks, subject to customary closing conditions.
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...
September 27, 2026 - 08:32
New Biochip Enables Real-Time Tracking of Parkinson's Treatment ResponseResearchers have created a biochip technology that allows for real-time monitoring of how Parkinson`s disease patients respond to treatment. The development comes from a team working on advanced...